{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:17:36Z","timestamp":1781176656316,"version":"3.54.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.revmed.2024.12.007","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:36:07Z","timestamp":1739363767000},"page":"146-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complications virales des bioth\u00e9rapies\/th\u00e9rapies cibl\u00e9es anti-inflammatoires"],"prefix":"10.1016","volume":"46","author":[{"given":"Lionel","family":"Piroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Sixt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.revmed.2024.12.007_bib0430","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.revmed.2024.12.007_bib0435","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2024.12.007_bib0440","doi-asserted-by":"crossref","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.revmed.2024.12.007_bib0445","series-title":"Definition of immunomodulating agent \u2014\u00a0NCI Dictionary of Cancer Terms\u00a0\u2014 NCI","year":"2011"},{"key":"10.1016\/j.revmed.2024.12.007_bib0450","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2024.12.007_bib0455","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.12.007_bib0460","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0465","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22575","article-title":"Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996\u20132011","volume":"67","author":"Tektonidou","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2024.12.007_bib0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2024.12.007_bib0475","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2024.12.007_bib0480","first-page":"3834","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2024.12.007_bib0485","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjz013","article-title":"Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality","volume":"13","author":"Zabana","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0490","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/apt.14420","article-title":"Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis","volume":"47","author":"Colombel","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2024.12.007_bib0495","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2024.12.007_bib0500","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-\u03b1 agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0505","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.mayocp.2021.05.029","article-title":"Corticosteroid use and risk of herpes zoster in a population-based cohort","volume":"96","author":"Qian","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2024.12.007_bib0510","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0515","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","article-title":"Risk of herpes\/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis","volume":"81","author":"Che","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2024.12.007_bib0520","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00228-013-1559-8","article-title":"Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials","volume":"69","author":"Wang","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.revmed.2024.12.007_bib0525","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2024.12.007_bib0530","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0535","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2024.12.007_bib0540","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0550","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.revmed.2024.12.007_bib0555","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1\u00a0and TULIP-2\u00a0trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0560","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0565","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3\u00a0trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.12.007_bib0570","doi-asserted-by":"crossref","first-page":"980079","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment","volume":"13","author":"Kirou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0575","doi-asserted-by":"crossref","first-page":"102505","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2024.12.007_bib0580","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.vaccine.2015.04.090","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.revmed.2024.12.007_bib0585","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2024.12.007_bib0590","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10\u00a0years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2024.12.007_bib0600","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0605","doi-asserted-by":"crossref","first-page":"e002621","DOI":"10.1136\/rmdopen-2022-002621","article-title":"Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data","volume":"8","author":"Dey","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2024.12.007_bib0610","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0615","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0620","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20\u00a0and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.revmed.2024.12.007_bib0625","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/v2071394","article-title":"Innate antiviral immune responses to hepatitis B virus","volume":"2","author":"Ait-Goughoulte","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.revmed.2024.12.007_bib0630","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0635","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.17155","article-title":"Meta-analysis: hepatitis B reactivation in patients receiving biological therapy","volume":"56","author":"El Jamaly","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2024.12.007_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.03.039","article-title":"Low but long-lasting risk of reversal of seroconversion in patients with rheumatoid arthritis receiving immunosuppressive therapy","volume":"18","author":"Chen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0645","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.revmed.2011.07.013","article-title":"[Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]","volume":"33","author":"Terrier","year":"2012","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.12.007_bib0650","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.11.024","article-title":"Patients treated with rituximab are poorly screened for hepatitis B infection: data from a low-incidence country","volume":"108","author":"Brakenhoff","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2024.12.007_bib0655","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiw011","article-title":"Vaccination against Hepatitis B Virus (HBV) in HIV-1-infected patients with isolated anti-HBV core antibody: the ANRS HB EP03\u00a0CISOVAC prospective study","volume":"213","author":"Piroth","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0660","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.14309\/ajg.0000000000002185","article-title":"A prospective study of preemptive tenofovir disoproxil fumarate therapy in HBsAg-positive patients with diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"118","author":"Kim","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0665","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022\u00a0EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0670","doi-asserted-by":"crossref","first-page":"e002726","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022\u00a0EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2024.12.007_bib0675","series-title":"Recommandations de prise en charge des personnes infect\u00e9es par le virus de l\u2019h\u00e9patite C","year":"2024"},{"key":"10.1016\/j.revmed.2024.12.007_bib0680","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0685","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0690","unstructured":"FR-TYS-Guide-Prescription-JUIN-2021.pdf 2021."},{"key":"10.1016\/j.revmed.2024.12.007_bib0695","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0700","doi-asserted-by":"crossref","first-page":"e2077","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20\u00a0monoclonal antibodies: what do we know after 20\u00a0years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0705","doi-asserted-by":"crossref","first-page":"e13148","DOI":"10.1111\/irv.13148","article-title":"Influenza-like illness in individuals treated with immunosuppressants, biologics, and\/or systemic corticosteroids for autoimmune or chronic inflammatory disease: a crowdsourced cohort study, France, 2017\u20132018","volume":"17","author":"Greffe","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.revmed.2024.12.007_bib0710","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ibd\/izy243","article-title":"Increased risk of influenza and influenza-related complications among 140,480\u00a0patients with inflammatory bowel disease","volume":"25","author":"Tinsley","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0715","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815\u00a0reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2024.12.007_bib0720","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.cmi.2023.08.028","article-title":"Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments","volume":"29","author":"Bouzid","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.revmed.2024.12.007_bib0725","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of severe RSV disease among immunocompromised children and adults: a 10-year retrospective study","volume":"18","author":"Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0730","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19\u00a0outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0735","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.16717","article-title":"Systematic review with meta-analysis: COVID-19\u00a0outcomes in patients receiving anti-TNF treatments","volume":"55","author":"Kokkotis","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2024.12.007_bib0740","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1007\/s10787-023-01349-z","article-title":"Systematic review and meta-analysis of anti-CD20\u00a0treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes","volume":"31","author":"Kow","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.revmed.2024.12.007_bib0745","doi-asserted-by":"crossref","first-page":"388e1","DOI":"10.1016\/j.cmi.2022.10.009","volume":"29","author":"Loubet","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.revmed.2024.12.007_bib0750","doi-asserted-by":"crossref","first-page":"e0273612","DOI":"10.1371\/journal.pone.0273612","article-title":"Efficacy and safety of SARS-CoV-2\u00a0vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: prospective observational study","volume":"17","author":"Wasserbauer","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.revmed.2024.12.007_bib0755","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1002\/jmv.28063","article-title":"The long term vaccine-induced anti-SARS-CoV-2\u00a0immune response is impaired in quantity and quality under TNF\u03b1 blockade","volume":"94","author":"Geisen","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0760","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.2671","article-title":"Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy","volume":"42","author":"Bemben","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.revmed.2024.12.007_bib0765","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0770","doi-asserted-by":"crossref","first-page":"e003400","DOI":"10.1136\/rmdopen-2023-003400","article-title":"COVID-19\u00a0Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12\u00a0months following Moderna Spikevax primary series","volume":"9","author":"Colmegna","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2024.12.007_bib0775","first-page":"565","article-title":"Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2\u00a0in patients with rheumatic pathology under biological treatment","volume":"19","author":"Flores-Fern\u00e1ndez","year":"2023","journal-title":"Rheumatol Clin"},{"key":"10.1016\/j.revmed.2024.12.007_bib0780","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19\u00a0vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2024.12.007_bib0785","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S2665-9913(23)00004-8","article-title":"Breakthrough SARS-CoV-2\u00a0infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study","volume":"5","author":"Yusof","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0790","doi-asserted-by":"crossref","first-page":"e2248664","DOI":"10.1001\/jamanetworkopen.2022.48664","article-title":"Analysis of rituximab use, time between rituximab and SARS-CoV-2\u00a0vaccination, and COVID-19\u00a0hospitalization or death in patients with multiple sclerosis","volume":"5","author":"Smith","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.revmed.2024.12.007_bib0795","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","article-title":"Vaccination of patients with autoimmune inflammatory rheumatic diseases","volume":"11","author":"Westra","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0800","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019\u00a0update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0805","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0810","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.12.007_bib0815","series-title":"Calendrier des vaccinations et recommandations vaccinales","year":"2024"},{"key":"10.1016\/j.revmed.2024.12.007_bib0820","series-title":"Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques. Recommandations actualis\u00e9es","year":"2014"},{"key":"10.1016\/j.revmed.2024.12.007_bib0825","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022\u00a0American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2024.12.007_bib0830","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2024.12.007_bib0835","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0840","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjv152","article-title":"Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and\/or biologics: a two-year prospective study","volume":"9","author":"Launay","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.revmed.2024.12.007_bib0845","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar2174","article-title":"Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects","volume":"9","author":"Tay","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2024.12.007_bib0425","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12026-021-09212-5","article-title":"Presence of specific T cell response after SARS-CoV-2\u00a0vaccination in rheumatoid arthritis patients receiving rituximab","volume":"69","author":"Benucci","year":"2021","journal-title":"Immunol Res"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324013456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324013456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:17:07Z","timestamp":1741004227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324013456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0248866324013456"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.12.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications virales des bioth\u00e9rapies\/th\u00e9rapies cibl\u00e9es anti-inflammatoires","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}